Investor Presentaiton

BND-35 restores T cell activity inhibited by various suppressive myeloid cells IFNg (pg/ml) DCtol + CD4 T cells 25,000 I 20,000 15,000 10.000 5,000 ○ iDC+CD4 T cells H Control IgG BND-35 DCtol + CD4 T cells BIOND BIOLOGICS DCtol, tolerogenic dendritic cells; MDSC, myeloid-derived suppressor cells Anti-tumor activity IFNg (pg/ml) BND-35 30,000 25,000 20,000 15,000 10.000 5,000 MDSC + CD8 T cells * H MDSCs naïve activated Medium control BND-35 T cell CD8 T cell IgG Controls CD8 T cells + MDSCs ILT3 Activated T cell * P<0.05; un-paired Student's T-test compared to control IgG Activated myeloid cells Biond Biologics Corporate Presentation | May 2021 | Non-confidential 涯 29 29

View entire presentation